Your browser doesn't support javascript.
loading
Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
Ruscito, Ilary; Cacsire Castillo-Tong, Dan; Vergote, Ignace; Ignat, Iulia; Stanske, Mandy; Vanderstichele, Adriaan; Glajzer, Jacek; Kulbe, Hagen; Trillsch, Fabian; Mustea, Alexander; Kreuzinger, Caroline; Benedetti Panici, Pierluigi; Gourley, Charlie; Gabra, Hani; Nuti, Marianna; Taube, Eliane T; Kessler, Mirjana; Sehouli, Jalid; Darb-Esfahani, Silvia; Braicu, Elena Ioana.
Afiliación
  • Ruscito I; Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany. ilary.ruscito@uniroma1.it.
  • Cacsire Castillo-Tong D; Cell Therapy Unit and Laboratory of Tumor Immunology, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. ilary.ruscito@uniroma1.it.
  • Vergote I; Translational Gynecology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
  • Ignat I; Division of Gynaecological Oncology, Leuven Cancer Institute, Department of Gynaecology and Obstetrics, University Hospital Leuven, Catholic University of Leuven, Herestraat 49, B-3000, Leuven, Belgium.
  • Stanske M; Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
  • Vanderstichele A; Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
  • Glajzer J; Division of Gynaecological Oncology, Leuven Cancer Institute, Department of Gynaecology and Obstetrics, University Hospital Leuven, Catholic University of Leuven, Herestraat 49, B-3000, Leuven, Belgium.
  • Kulbe H; Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
  • Trillsch F; Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
  • Mustea A; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistrasse 15, Munich, Germany.
  • Kreuzinger C; Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Martinistr. 46, Hamburg, Germany.
  • Benedetti Panici P; Department of Gynecology and Obstetrics, University Medicine of Greifswald, Greifswald, Germany.
  • Gourley C; Translational Gynecology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.
  • Gabra H; Department of Gynecology, Obstetrics and Urology, Sapienza University of Rome, Rome, Italy.
  • Nuti M; Nicola Murray Centre for Ovarian Cancer Research, MRC IGMM, Western General Hospital, University of Edinburgh Cancer Research, UK Centre, Crewe Road South, Edinburgh, EH4 2XR, UK.
  • Taube ET; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Kessler M; Clinical Discovery Unit, AstraZeneca, Cambridge, UK.
  • Sehouli J; Cell Therapy Unit and Laboratory of Tumor Immunology, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
  • Darb-Esfahani S; Institute of Pathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
  • Braicu EI; Department of Molecular Biology, Max Planck Institute for Infection Biology, Berlin, Germany.
Br J Cancer ; 119(3): 330-338, 2018 08.
Article en En | MEDLINE | ID: mdl-29955134
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Cistadenocarcinoma Seroso / Molécula-1 de Adhesión Celular Endotelial de Plaqueta / Factor A de Crecimiento Endotelial Vascular / Neovascularización Patológica Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Br J Cancer Año: 2018 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Cistadenocarcinoma Seroso / Molécula-1 de Adhesión Celular Endotelial de Plaqueta / Factor A de Crecimiento Endotelial Vascular / Neovascularización Patológica Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Br J Cancer Año: 2018 Tipo del documento: Article País de afiliación: Alemania